China Dasheng Biotechnology Company

CDBT · Other OTC · USD

0,10USD

0,00 (0,00 %)Stand 13. Juni, 0:00

Vortag 0,10

Kennzahlen

Eröffnung
0,06
Vortag
0,10
Tagesspanne
0,06 – 0,10
52 Wochen
0,0003 – 0,15
Volumen
10.000
Ø Volumen
6026
Börsenwert
4,1 Mio. $
KGV
-4,2
Gewinn je Aktie (TTM)
-0,01
Dividendenrendite
0,0 %
Beta
2,3
Nächste Zahlen
–

Finanzen

USDFY 2022FY 2007FY 2006FY 2005FY 2004
Umsatz016,29 Mio.0484.838630.692
Herstellungskosten08,79 Mio.1620365.030406.695
Bruttogewinn07,5 Mio.−1620119.808223.997
Forschung und Entwicklung00000
Vertrieb und Verwaltung560.9352,43 Mio.8380136.672246.742
Operatives Ergebnis−657.0005,08 Mio.−10.000−16.864−22.745
EBITDA−637.0005,7 Mio.−8380−15.244−21.125
Nettogewinn−967.0004,64 Mio.−68.447−16.864−22.745
Gewinn je Aktie (verwässert)-0,020,15-0,01-0,00-0,00

Bewertung

Letzte 12 Monate

KGV
-4,2
Kurs-Umsatz-Verhältnis
0,0
Kurs-Buchwert-Verhältnis
-3,4
PEG
0,1
Bruttomarge
0,0 %
Operative Marge
0,0 %
Nettomarge
0,0 %
Verschuldungsgrad
-0,8
EV/EBITDA
-8,0
Eigenkapitalrendite
155,5 %
Kapitalrendite (ROIC)
354,7 %
Free-Cashflow-Rendite
−5,7 %
FY 2022FY 2021FY 2007FY 2006FY 2005
Bruttomarge0,0 %0,0 %46,1 %0,0 %24,7 %
Operative Marge0,0 %0,0 %31,1 %0,0 %−3,5 %
Nettomarge0,0 %0,0 %28,5 %0,0 %−3,5 %
KGV-3,10,013,0-200,0-1.052,6
Kurs-Umsatz-Verhältnis0,00,03,60,037,5
Kurs-Buchwert-Verhältnis-2,50,03,70,0-47.769,0
Verschuldungsgrad-0,80,00,00,00,0
Liquidität 3. Grades0,10,05,50,00,7
Dividendenrendite0,0 %0,0 %0,0 %0,0 %0,0 %
Unternehmenswert4,05 Mio.056,94 Mio.018,19 Mio.
EV/EBITDA-6,40,010,00,0-1.193,4
Eigenkapitalrendite79,7 %0,0 %29,6 %0,0 %4.426,2 %
Kapitalrendite (ROIC)354,7 %0,0 %27,1 %0,0 %0,0 %
Free-Cashflow-Rendite−7,7 %0,0 %7,0 %0,0 %0,0 %

Wachstum

FY 2022FY 2021FY 2007FY 2006FY 2005
Umsatz0,0 %0,0 %0,0 %−100,0 %−23,1 %
Bruttogewinn0,0 %0,0 %+463.309,9 %−101,4 %−46,5 %
Operatives Ergebnis0,0 %0,0 %+50.850,0 %+40,7 %+25,9 %
Nettogewinn0,0 %0,0 %+6.876,0 %−305,9 %+25,9 %
Gewinn je Aktie0,0 %0,0 %+1.600,0 %−426,3 %+24,0 %
Freier Cashflow0,0 %0,0 %0,0 %0,0 %0,0 %
Dividende je Aktie0,0 %0,0 %0,0 %0,0 %0,0 %

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

März 2009Dez. 2008Sept. 2008März 2008Dez. 2007Juli 2007Apr. 2007Jan. 2007
Gewinn je Aktie · Erwartet––––––––
Gewinn je Aktie · Tatsächlich0,040,060,040,010,05-0,00-0,00-0,00
Abweichung––––––––
Umsatz · Tatsächlich5,31 Mio.5,66 Mio.5,11 Mio.3,71 Mio.4,71 Mio.96.56090.27078.955

Dividenden und Splits

Keine Dividenden gezahlt.

Aktiensplits

–

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

–

Vergleichbare Unternehmen

Über das Unternehmen

China Dasheng Biotechnology Company, alongside its various divisions, is dedicated to the creation, promotion, and distribution of microbial products within the People's Republic of China. These specialized solutions primarily function as beneficial additives for both livestock feed and agricultural cultivation. The company's product line features proprietary blends of Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM), in addition to biological preservatives. Its AM/HM bacteria-based additives for crops, including specific strains like Bulgaria lactobacillus, beer microzyme, and dark red spirilla, are formulated to significantly boost beneficial microbial populations in soil. They also work to counteract the proliferation of harmful fungi and putrefactive bacteria, thereby optimizing nutrient absorption and helping to reduce the incidence of diseases in both plants and animals. For animal nutrition, the AM/HM bacteria-based feed additives are designed to improve the texture of livestock feed and inhibit the growth of pathogenic bacteria. Moreover, they deliver essential nutrients such as organic acids, vitamins, enzymes, natural antibiotics, mycelial protein, and various other growth-promoting substances to ensure a balanced nutritional profile in the feed. The FGW bacterial preservatives serve a dual purpose: preserving animal specimens for scientific research and extending the shelf life of agricultural produce. Furthermore, the company supplies bacteria-based fertilizers intended for application directly onto plant foliage, particularly for vegetables and fruits. Beyond its biotechnology endeavors, China Dasheng Biotechnology Company also holds investments in the residential and commercial real estate sectors. The enterprise was previously known as Max Nutrition, Inc., before officially adopting its current name, China Dasheng Biotechnology Company, in March 2008. Its operational headquarters are situated in Lanzhou, China.

Führung

  • Jinjun QiPresident & Secretary
  • Gang ChenChairman of the Board & Chief Executive Officer
  • Hongsheng WangChief Financial Officer
  • Jingbo GaoVice President of Investor Relations
CEO
Gang Chen
Mitarbeitende
689
Hauptsitz
Lanzhou, CN
Sektor
Financial Services
Branche
Shell Companies
Börsengang
13. Feb. 2008

Nachrichten

Gerade keine Nachrichten zu diesem Unternehmen.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.